140 related articles for article (PubMed ID: 11285159)
21. Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine.
Luzzati R; Di Perri G; Fendt D; Ramarli D; Broccali G; Concia E
J Antimicrob Chemother; 1998 Oct; 42(4):565-6. PubMed ID: 9818769
[No Abstract] [Full Text] [Related]
22. [Hydroxyurea and HIV infection].
Nkoghe D; Kola L; Léonard P; Demonty J; Moutschen M
Rev Med Liege; 2000 Jul; 55(7):721-4. PubMed ID: 11014107
[TBL] [Abstract][Full Text] [Related]
23. Hydroxyurea for HIV?
Treat Rev; 1998; (No 28):10-2. PubMed ID: 11365419
[TBL] [Abstract][Full Text] [Related]
24. Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients.
Bakshi RP; Hamzeh F; Frank I; Eron JJ; Bosch RJ; Rosenkranz SL; Cramer YS; Ussery M; Flexner C
AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1360-5. PubMed ID: 18184078
[TBL] [Abstract][Full Text] [Related]
25. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
[TBL] [Abstract][Full Text] [Related]
26. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.
Japour AJ; Lertora JJ; Meehan PM; Erice A; Connor JD; Griffith BP; Clax PA; Holden-Wiltse J; Hussey S; Walesky M; Cooney E; Pollard R; Timpone J; McLaren C; Johanneson N; Wood K; Booth D; Bassiakos Y; Crumpacker CS
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Nov; 13(3):235-46. PubMed ID: 8898668
[TBL] [Abstract][Full Text] [Related]
27. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.
Montaner JS; Zala C; Conway B; Raboud J; Patenaude P; Rae S; O'Shaughnessy MV; Schechter MT
J Infect Dis; 1997 Apr; 175(4):801-6. PubMed ID: 9086133
[TBL] [Abstract][Full Text] [Related]
28. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
Lori F; Rosenberg E; Lieberman J; Foli A; Maserati R; Seminari E; Alberici F; Walker B; Lisziewicz J
AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1333-8. PubMed ID: 10515148
[TBL] [Abstract][Full Text] [Related]
29. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
Paton NI; Aboulhab J
HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247
[TBL] [Abstract][Full Text] [Related]
30. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.
Mobley JE; Pollard RB; Schrader S; Adler MH; Kelleher T; McLaren C
AIDS; 1999 Jul; 13(11):F87-93. PubMed ID: 10449279
[TBL] [Abstract][Full Text] [Related]
31. Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
Lori F; Pollard RB; Whitman L; Bakare N; Blick G; Shalit P; Foli A; Peterson D; Tennenberg A; Schrader S; Rashbaum B; Farthing C; Herman D; Norris D; Greiger P; Frank I; Groff A; Lova L; Asmuth D; Lisziewicz J
AIDS Res Hum Retroviruses; 2005 Apr; 21(4):263-72. PubMed ID: 15943568
[TBL] [Abstract][Full Text] [Related]
32. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; 2000(2):CD002038. PubMed ID: 10796851
[TBL] [Abstract][Full Text] [Related]
33. Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1.
Paton NI; Aboulhab J; Karim F
Lancet; 2002 May; 359(9318):1667-8. PubMed ID: 12020529
[TBL] [Abstract][Full Text] [Related]
34. Hydroxyurea - new observations.
Proj Inf Perspect; 1998 Apr; (24):15-7. PubMed ID: 11365714
[TBL] [Abstract][Full Text] [Related]
35. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.
Foli A; Lori F; Maserati R; Tinelli C; Minoli L; Lisziewicz J
Antivir Ther; 1997 Jan; 2(1):31-8. PubMed ID: 11322264
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
37. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
Demeter LM; Meehan PM; Morse G; Gerondelis P; Dexter A; Berrios L; Cox S; Freimuth W; Reichman RC
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):136-44. PubMed ID: 9052722
[TBL] [Abstract][Full Text] [Related]
39. Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
Laurent C; Tchatchueng Mbougua JB; Ngom Guèye NF; Etard JF; Diouf A; Landman R; Molinari N; Girard PM; Sow PS; Ndoye I; Delaporte E;
Trop Med Int Health; 2011 Feb; 16(2):217-22. PubMed ID: 21087377
[TBL] [Abstract][Full Text] [Related]
40. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy.
De Antoni A; Foli A; Lisziewicz J; Lori F
J Infect Dis; 1997 Oct; 176(4):899-903. PubMed ID: 9333147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
